Ischaemic Stroke Circulatory System Cerebral infarction
Conditions
Interventions
Eligible patients who have provided consent will be randomly assigned to receive either dexamphetamine or placebo control. Dexamphetamine or placebo control will be administered orally twice a week wi
Sponsors
University of Nottingham (UK)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Clinical stroke 3-30 days post ictus 2. Ischaemic stroke on computed tomography (CT)/magnetic resonance imaging (MRI) 3. Motor weakness (Motricity Index arm 0-99 inclusive) 4. Patients expected to stay in hospital for a further 8 days
Exclusion criteria
Exclusion criteria: 1. Pre-morbid Barthel Index 160 or diastolic BP >100) 5. Clinical ischaemic heart disease, previous or current angina, myocardial infarction 6. Hyperexcitability or agitated states 7. Current hyperthyroidism 8. History of alcohol or drug abuse 9. Glaucoma 10. Predisposition to tics or Tourette Syndrome 11. Epilepsy or recent convulsions 12. Liver dysfunction (aspartate aminotransferase [AST] 3 x normal) 13. Renal dysfunction (creatinine >130) 14. Pregnancy and breastfeeding 15. Recent monoamine oxidase inhibitor (MAOI) usage 16. Porphyria
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The safety, tolerabilty and feasibility of dexamphetamine in acute ischaemic stroke and its effect on motor impairment, cerebral and cardiac haemodynamics. | — |
Secondary
| Measure | Time frame |
|---|---|
| At outcome (35 days) and follow up (90 days): Modified Rankin, Barthel Index, SNSS, Motricity Index, Grip Strength, Thumb-finding test, Sheffield aphasia screening, modified Mini-Mental State Examination (MMSE), Zung depression, EuroQUOL, 10-Hole Peg Test. | — |
Countries
United Kingdom
Outcome results
None listed